Aggressive Lymphomas
News
First CAR T-cell therapy approved in Canada
Health Canada has authorized use of tisagenlecleucel (Kymriah™), making it the first chimeric antigen receptor (CAR) T-cell therapy to receive...
News
Regimens produce similar results in FL
Rituximab plus lenalidomide had efficacy similar to that of rituximab plus chemotherapy in the treatment of follicular lymphoma (FL) in a phase 3...
News
Ibrutinib maintains efficacy over time
Extended follow-up of the RESONATE-2 trial showed that first-line ibrutinib sustained efficacy in elderly patients with chronic lymphocytic...
From the Journals
RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients
Adverse events were largely seen during the first year of treatment and decreased over time.
Feature
England green-lights coverage of one CAR T-cell therapy
Tisagenlecleucel (Kymriah) will be available for certain leukemia patients through the Cancer Drugs Fund.
From the Journals
Researchers find drug target in anaplastic large-cell lymphoma
A new study suggests TYK2 is expressed in all cases of ALCL.
From the Journals
Adverse events outweigh promise of SGN-CD70A against NHL
Despite a handful of durable remissions of non-Hodgkin lymphomas with the antibody-drug conjugate, thrombocytopenias canceled out the benefit.
News
Predicting early outcomes in DLBCL
Measurement of circulating tumor DNA (ctDNA) could be a new and useful tool for predicting survival outcomes and response to therapy in patients...
Feature
New BTK inhibitor under review in China
Zanubrutinib is being reviewed for treatment of relapsed/refractory mantle cell lymphoma.
News
NICE says CAR T-cell therapy isn’t cost-effective
The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending against the use of axicabtagene ciloleucel (...
Latest News
European Commission approves first CAR T-cell therapies
Tisagenlecleucel and axicabtagene ciloleucel can now be marketed throughout Europe.